Molecular Partners AG - Asset Resilience Ratio

Latest as of September 2025: 19.76%

Molecular Partners AG (MOLN) has an Asset Resilience Ratio of 19.76% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check MOLN capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CHF22.16 Million

≈ $28.02 Million USD Cash + Short-term Investments

Total Assets

CHF112.15 Million

≈ $141.79 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how Molecular Partners AG's Asset Resilience Ratio has changed over time. See MOLN equity to assets ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Molecular Partners AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Molecular Partners AG market cap and net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CHF0.00	0%
Short-term Investments	CHF22.16 Million	19.76%
Total Liquid Assets	CHF22.16 Million	19.76%

Asset Resilience Insights

Good Liquidity Position: Molecular Partners AG maintains a healthy 19.76% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Molecular Partners AG Industry Peers by Asset Resilience Ratio

Compare Molecular Partners AG's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Molecular Partners AG (2015–2024)

The table below shows the annual Asset Resilience Ratio data for Molecular Partners AG.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	53.97%	CHF85.56 Million ≈ $108.18 Million	CHF158.53 Million ≈ $200.42 Million	-6.31pp
2023-12-31	60.29%	CHF119.58 Million ≈ $151.18 Million	CHF198.35 Million ≈ $250.77 Million	-1.18pp
2022-12-31	61.47%	CHF161.20 Million ≈ $203.80 Million	CHF262.26 Million ≈ $331.56 Million	+26.14pp
2021-12-31	35.33%	CHF61.00 Million ≈ $77.12 Million	CHF172.67 Million ≈ $218.30 Million	+14.00pp
2020-12-31	21.33%	CHF40.00 Million ≈ $50.57 Million	CHF187.55 Million ≈ $237.11 Million	+2.87pp
2019-12-31	18.46%	CHF19.37 Million ≈ $24.49 Million	CHF104.94 Million ≈ $132.67 Million	--
2018-12-31	0.00%	CHF0.00 ≈ $0.00	CHF155.16 Million ≈ $196.16 Million	--
2017-12-31	6.75%	CHF9.74 Million ≈ $12.32 Million	CHF144.42 Million ≈ $182.59 Million	-9.81pp
2016-12-31	16.56%	CHF30.49 Million ≈ $38.55 Million	CHF184.10 Million ≈ $232.75 Million	+7.44pp
2015-12-31	9.13%	CHF20.02 Million ≈ $25.31 Million	CHF219.40 Million ≈ $277.38 Million	--

pp = percentage points

About Molecular Partners AG

SW:MOLN Switzerland Biotechnology

Market Cap

$147.52 Million

CHF116.69 Million CHF

Market Cap Rank

#17845 Global

#181 in Switzerland

Share Price

CHF3.12

Change (1 day)

-0.32%

52-Week Range

CHF2.75 - CHF3.95

All Time High

CHF38.40